Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Company calls its solution The Vivos Method. The Vivos Method represents the first clinically effective nonsurgical, noninvasive and nonpharmaceutical solution for treating mild to severe OSA. The Vivos Method includes treatment regimens that employ the proprietary Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient's upper airway and/or palate. The Vivos Method comprises various products and services, including Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, and Vivos Airway Intelligence Service.
Ticker SymbolVVOS
Company nameVivos Therapeutics Inc
IPO dateDec 11, 2020
CEOMr. R. Kirk Huntsman
Number of employees109
Security typeOrdinary Share
Fiscal year-endDec 11
Address7921 Southpark Plaza,
CityLITTLETON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code80120
Phone18669084867
Websitehttps://vivos.com/
Ticker SymbolVVOS
IPO dateDec 11, 2020
CEOMr. R. Kirk Huntsman
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data